Fouremm,

Very nice post about ESPR. I don't have too much to add. I had a small position in ESPR that I sold in September 2014 after some solid Phase II news. However, I sold at ~$20 to book a small profilt, not expecting it to keep rising to above $100 and the ESPR market cap to rise above $2B. Obviously, the market was already treating ESPR and its ETC-1002 like Phase III was a done deal. Because of this, ESPR doesn't have too much upside anymore in my opinion. The PCSK9 antibody therapy approval eats up a chunk of the ETC-1002 market. Plus, more statin alternative are on the way (e.g. Catabasis). So LDL lowering is quite the saturated market. One benefit of the LDL-lowering therapies is that it seems that the FDA isn't requiring cardiovascular outcomes trials (see latest ESPR press release).

As you summed up, RVX has a lot more baggage. But hopefully, the past will be forgiven soon enough and the market will realize the huge upside potential of RVX-208 going into Phase 3 BETonMACE and price it accordingly. However, until the curtain is pulled back on the closely guarded details of BETonMACE or the fabled orphan indication, we might not see much action.

12 days until the first of the fall presenations (August 30th)

6 weeks + 1 day until the AGM

Fall is getting closer.